MAO-A: A Key Enzyme in Neurotransmitter Metabolism and Drug Target

Target Name: CYP2C18

NCBI ID: G1562

CYP2C18

MAO-A: A Key Enzyme in Neurotransmitter Metabolism and Drug Target

CYP2C18 is a gene that encodes for a protein known as the monoamine oxidase (MAO) subunit, which is a key enzyme in the metabolism of neurotransmitters such as dopamine, norepinephrine, and serotonin. This gene is located on chromosome 11 and has been implicated in the treatment of various psychiatric and neurological disorders, including depression, anxiety, and psychosis.

The CYP2C18 gene has been the focus of extensive research in recent years, largely due to its involvement in the metabolism of certain drugs, such as antidepressants and psychostimulants. The MAO subunit is known to be a drug target, meaning that it is the target of drugs that aim to modulate its activity. This is because the MAO subunit plays a crucial role in the metabolism of these drugs, and changes in its activity can have a significant impact on the therapeutic effects of these drugs.

One of the main ways that MAO-A is involved in drug metabolism is through its role in the metabolism of monoamine neurotransmitters. These neurotransmitters play a critical role in the brain and are involved in a wide range of physiological processes, including mood regulation, pain perception, and social behavior. The MAO-A enzyme is responsible for breaking down many of these neurotransmitters, including dopamine, norepinephrine, and serotonin.

The CYP2C18 gene has also been shown to play a role in the metabolism of other drugs, including some antidepressants and psychostimulants. For example, some studies have suggested that MAO-A may be involved in the metabolism of selective serotonin reuptake inhibitors (SSRIs), which are commonly used to treat depression and anxiety. Other studies have suggested that MAO-A may be involved in the metabolism of other drugs, such as ADHD medications and some epilepsy treatments.

In addition to its role in drug metabolism, MAO-A is also thought to be involved in the regulation of other physiological processes in the body. For example, some studies have suggested that MAO-A may be involved in the regulation of blood pressure, and that changes in its activity may have an impact on this process. Other studies have suggested that MAO-A may be involved in the regulation of body weight and metabolism, and that changes in its activity may have an impact on these processes.

Overall, the CYP2C18 gene has been the subject of intense research in recent years, largely due to its involvement in the metabolism of drugs and its potential as a drug target. While further research is needed to fully understand the role of MAO-A in drug metabolism and other physiological processes, its potential as a drug target is an exciting area of 鈥嬧?媟esearch that could have significant implications for the treatment of psychiatric and neurological disorders.

Protein Name: Cytochrome P450 Family 2 Subfamily C Member 18

Functions: A cytochrome P450 monooxygenase involved in retinoid metabolism. Hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may modulate atRA signaling and clearance. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase)

The "CYP2C18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2C18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets